Quarterly ResultAug 6, 2026, 07:47 AM
Intellia Reports Positive Lonvo-z Phase 3 Data, Q2 Results
AI Summary
Intellia Therapeutics announced its second quarter 2026 financial results and business updates, highlighted by positive Phase 3 HAELO clinical data for lonvo-z in hereditary angioedema (HAE), which showed an 87% reduction in attacks versus placebo. The company anticipates FDA BLA acceptance for lonvo-z in the second half of 2026 and a U.S. launch in the first half of 2027. Enrollment for nex-z Phase 3 clinical trials has been reinitiated, with MAGNITUDE-2 enrollment expected to be completed in the second half of 2026. Intellia reported a net loss of $106.6 million for Q2 2026 and ended the quarter with approximately $628 million in cash, expected to fund operations at least into 2028.
Key Highlights
- Lonvo-z Phase 3 HAELO trial reduced HAE attacks by 87% vs. placebo.
- 62% of lonvo-z patients were attack-free and therapy-free for six months.
- FDA BLA acceptance for lonvo-z anticipated in H2 2026; U.S. launch H1 2027.
- MAGNITUDE-2 enrollment for nex-z expected to be completed in H2 2026.
- Q2 2026 net loss was $106.6 million, compared to $101.3 million in Q2 2025.
- Q2 2026 collaboration revenue was $7.7 million, down from $14.2 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $628.4 million as of June 30, 2026.
- Existing cash resources expected to fund operations at least into 2028.
Price Impact
More from NTLA